Report : North America Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)
Human Segment has the Largest Share of Source in the North America Monoclonal Antibodies Market during 2021–2028
According to our latest study on “North America Monoclonal Antibodies Market Forecast to 2028 – COVID-19 Impact and Analysis – by Source, Production Method, Indication, Application, and End User,” the market is projected to reach US$ 1,20,713.2 million by 2028 from US$ 54,629.4 million in 2021; it is expected to grow at a CAGR of 12.0% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the rising prevalence of cancer and other chronic diseases, mABs uptake proves to be effective during pandemic outbreaks. However, low awareness, accessibility, and high cost is expected to restrict the market growth during the forecast period.
Favorable government regulations in North America regional market authorizes monoclonal antibodies during the onset of the pandemic. For instance, in December 2021, The US Food and Drug Administration (FDA) announced Emergency Use Authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) intended for pre-exposure prophylaxis of COVID-19 for certain adults and pediatric individuals. As monoclonal antibodies are laboratory manufactured proteins involved in mimicking the immune system's ability to fight off harmful pathogens such as viruses. Therefore, "Tixagevimab" and "cilgavimab" are long-acting monoclonal antibodies particularly directed for spike protein of SARS-CoV-2. Apart from that, favorable funding for development of biologics further enhanced the market growth for monoclonal antibodies during the onset of pandemic in North America regional market. For example, the US International Development Finance Corporation (DFC) announced furnishing of US$50 million to Biological E Limited for increasing COVID-19 vaccine manufacturing capacity. Also, favorable policy relating to product approvals for biologics by the FDA positively impacts the market growth.
Based on source, the Monoclonal Antibodies (mAbs) market is segmented into human, humanized, chimeric, and murine. In 2020, the human segment accounted for the highest share, moreover the same segment is expected to grow at a CAGR of 12.7% in the forecast period.
Novartis AG, Pfizer Inc., GlaxoSmithKline plc., Amgen Inc., DAIICHI SANKYO COMPANY, LIMITED, F. Hoffmann-La Roche Ltd., AstraZeneca, Eli Lilly and Company, Bayer AG, and Bristol-Myers Squibb Company are among the leading companies in the North America monoclonal antibodies market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
The market for monoclonal antibodies market is segmented into source, production method, indication, application, and end user. Based on source, the North America monoclonal antibodies market is segmented into human, humanized, chimeric, murine. Based on production method, the monoclonal antibodies market is segmented into in-vitro, in-vivo. Based on indication, the monoclonal antibodies market is segmented into cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, others. Based on application, the monoclonal antibodies market is segmented into therapeutic applications, diagnostic applications, research applications. Based on end user, the monoclonal antibodies market is segmented into hospitals, research institutes, others. Geographically, the monoclonal antibodies market is segmented into North America (US, Canada, Mexico).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com